YS Biopharma Repays $40M Loan
Ticker: LSBWF · Form: 6-K · Filed: Apr 3, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Ys Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Apr 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $40,000,000 |
| Sentiment | bullish |
Sentiment: bullish
Topics: debt-repayment, financial-health, cash-flow
TL;DR
YS Biopharma just paid off its $40M loan using cash flow. Big win for financials.
AI Summary
YS Biopharma Co., Ltd. announced on April 3, 2024, the full repayment of its US$40,000,000 loan facility. This repayment was made using funds from the company's operating cash flow.
Why It Matters
The full repayment of a significant loan facility indicates improved financial health and potentially reduces future interest expenses for YS Biopharma.
Risk Assessment
Risk Level: low — The filing reports a positive financial event (loan repayment) with no immediate negative implications.
Key Numbers
- $40.0B — Loan Facility Repayment (YS Biopharma fully repaid its US$40,000,000 loan facility using operating cash flow.)
Key Players & Entities
- YS Biopharma Co., Ltd. (company) — Filer of the report and borrower of the loan
- US$40,000,000 (dollar_amount) — Amount of the loan facility fully repaid
- April 3, 2024 (date) — Date of the announcement and repayment
FAQ
What was the total amount of the loan facility that YS Biopharma announced it has fully repaid?
YS Biopharma announced the full repayment of its US$40,000,000 loan facility.
When was the announcement of the loan repayment made?
The announcement was made on April 3, 2024, as part of a Form 6-K filing.
How did YS Biopharma fund the repayment of the loan facility?
The repayment was funded using the company's operating cash flow.
What is the Commission File Number for this filing?
The Commission File Number for this 6-K filing is 001-41598.
What is the primary business of YS Biopharma Co., Ltd. according to the filing?
YS Biopharma Co., Ltd. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 217 words · 1 min read · ~1 pages · Grade level 9.3 · Accepted 2024-04-03 08:10:02
Key Financial Figures
- $40,000,000 — Biopharma Announces Full Repayment of US$40,000,000 Loan Facility Exhibit 99.1 to this Cu
Filing Documents
- ea0203229-6k_ysbiophar.htm (6-K) — 10KB
- ea020322901ex99-1_ysbiophar.htm (EX-99.1) — 8KB
- 0001213900-24-029585.txt ( ) — 19KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. YS Biopharma Co., Ltd. Date: April 3, 2024 By: /s/ Hui Shao Name: Hui Shao Title: Director and Chief Executive Officer 2